Medigen Vaccine Biologics Company Description

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.

It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses.

The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19.

The company was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation operates as a subsidiary of Medigen Biotechnology Corp.